Poolbeg Pharma, a company focused on innovative medicines,m] has announced promising in vivo results for POLB 001 in treating cancer immunotherapy-induced cytokine release syndrome (CRS).
The drug showed efficacy in significantly reducing the condition in an animal model with CRS symptoms.
The data further supports Poolbeg’s strategic expansion of the phase II-ready POLB 001 while the emerging results facilitate the expansion of patent applications for the therapy.
As an oral therapy to prevent or treat CRS, POLB 001 has the potential to enable a broader use of cancer immunotherapies in an outpatient setting.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
